Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $195.00

Axsome Therapeutics (NASDAQ:AXSM) had its target price boosted by Mizuho from $137.00 to $195.00 in a report published on Tuesday morning,Benzinga reports. They currently have an outperform rating on the stock.

AXSM has been the topic of several other reports. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 target price on shares of Axsome Therapeutics in a research report on Monday. William Blair reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a research report on Friday, January 24th. Truist Financial upped their target price on Axsome Therapeutics from $180.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft assumed coverage on Axsome Therapeutics in a research report on Tuesday. They set a “buy” rating and a $176.00 target price on the stock. Finally, Robert W. Baird upped their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $147.13.

Axsome Therapeutics Trading Up 0.1 %

AXSM opened at $131.68 on Tuesday. The firm has a market cap of $6.38 billion, a price-to-earnings ratio of -20.17 and a beta of 1.05. The company has a current ratio of 2.44, a quick ratio of 2.37 and a debt-to-equity ratio of 1.97. Axsome Therapeutics has a 12 month low of $64.11 and a 12 month high of $134.18. The stock has a fifty day moving average price of $96.55 and a 200-day moving average price of $92.67.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same period in the prior year, the company posted ($1.32) EPS. As a group, equities research analysts anticipate that Axsome Therapeutics will post -4.7 earnings per share for the current fiscal year.

Institutional Trading of Axsome Therapeutics

A number of hedge funds have recently modified their holdings of the stock. FMR LLC boosted its stake in shares of Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after buying an additional 185,951 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Axsome Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 912,538 shares of the company’s stock worth $77,228,000 after buying an additional 4,079 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Axsome Therapeutics by 1.1% in the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock worth $66,750,000 after buying an additional 8,125 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Axsome Therapeutics by 10.8% in the fourth quarter. Invesco Ltd. now owns 692,464 shares of the company’s stock worth $58,589,000 after buying an additional 67,285 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Axsome Therapeutics in the fourth quarter worth about $34,100,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.